Zinc Carnosine: What the Research Reports

Zinc carnosine, also known as polaprezinc, is a chelate compound in which a zinc ion is bound to the dipeptide L-carnosine in a one to one ratio. Because the molecule carries both a mineral and a dipeptide, published studies have examined it from two angles: as a source of elemental zinc for people with low zinc status, and as a compound studied alongside gastric therapies. This page summarises what human studies in the cited literature describe, including population, comparator, endpoint and result, and it describes the adverse events those papers recorded. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

What Zinc Carnosine Is

Zinc carnosine is a coordination compound formed from zinc and L-carnosine, a dipeptide of beta-alanine and L-histidine. The zinc portion is why the compound appears in trials of zinc deficiency, and the carnosine portion is why it appears in reviews of carnosine-containing interventions, such as a systematic review and meta-analysis of L-carnosine in age-related diseases (PMID 36722274). The dipeptide itself is covered separately in the PeptideU guide on what carnosine is used for, so this page focuses on the chelate rather than on free carnosine.

In the published literature the compound is usually written as polaprezinc, the name used in most Japanese and Chinese clinical research, while "zinc carnosine" is the more common label in English language supplement contexts. A randomized controlled study of Helicobacter pylori eradication published in 2022 used the term zinc carnosine in its title while describing the same chelate (PMID 35071521).

Gastric Endpoints and Helicobacter pylori Eradication

Most human research touching the gastric mucosa has studied zinc carnosine as a component of combination eradication regimens rather than as a stand-alone gastric treatment.

Randomized comparisons

A randomized controlled study compared zinc carnosine-based modified bismuth quadruple therapy with standard triple therapy in patients with Helicobacter pylori infection, with eradication rate as the primary endpoint, and researchers reported eradication outcomes for the modified regimen alongside recorded adverse events (PMID 35071521). A separate randomized controlled trial examined the effect of quadruple therapy containing either polaprezinc or bismuth on the gut microbiota after eradication, and the study reported microbiota composition following treatment as its outcome of interest rather than eradication alone (PMID 36498624).

A published protocol described a planned single-centre, single-blind, non-inferiority randomised clinical trial of a quadruple regimen with polaprezinc for gastric Helicobacter pylori infection, and because protocols set out design rather than findings, that paper reported no efficacy results (PMID 33203625).

Pooled analysis

A systematic review and meta-analysis of randomized controlled trials compared polaprezinc-based therapy with standard triple therapy for Helicobacter pylori eradication and assessed both efficacy and safety, with eradication rate and adverse event frequency as the pooled endpoints; the researchers reported that polaprezinc-based regimens achieved higher eradication rates than standard triple therapy in the pooled trials (PMID 36235778). Pooled analyses of this kind combine trials that differ in antibiotic backbone, duration and region, which is a limitation the review format itself acknowledges (PMID 36235778).

Zinc Status and Zinc Deficiency

Because the chelate delivers elemental zinc, several trials have compared it with other zinc salts in populations prone to low zinc.

A randomized clinical trial compared zinc acetate hydrate supplementation with polaprezinc supplementation for improving hypozincemia in hemodialysis patients, using serum zinc concentration as the endpoint of comparison (PMID 37840640). An earlier single-center, open-label, prospective randomized study compared zinc acetate hydrate and polaprezinc for zinc deficiency in patients on maintenance hemodialysis, again with serum zinc as the comparator endpoint (PMID 31794152). Both papers framed the question as which zinc preparation corrected low serum zinc in dialysis patients, not whether zinc carnosine produced effects beyond its zinc content (PMID 37840640).

A systematic review and dose-response meta-analysis using individual patient data evaluated the efficacy and safety of polaprezinc in zinc deficiency, and the researchers examined the relationship between the amount administered and the change in zinc status across the included randomized trials (PMID 32316581). Individual patient data analyses pool raw participant records rather than published summary figures, which the authors of that review used to model the dose-response relationship (PMID 32316581).

Taste Disorders

A randomized, double-blind, placebo-controlled, multi-center study examined polaprezinc in patients with taste disorders, comparing active treatment against placebo with taste function as the endpoint, and the study reported that the zinc-containing compound was effective in that population (PMID 19037756). A broader systematic review of taste disorder management surveyed the available interventions, including zinc compounds, and summarised the strength of the evidence behind each approach (PMID 32385655).

Oral Mucositis During Transplantation Chemotherapy

A multi-institutional randomized controlled trial studied polaprezinc for the prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation, with the occurrence of oral mucositis as the trial endpoint (PMID 32984946). That trial sits in a hospital setting with a highly selected population, so its design does not generalise to healthy adults, a point implicit in the transplantation inclusion criteria the study used (PMID 32984946).

Cardiac Function After Myocardial Infarction

A prospective and randomized clinical trial assessed the effect of polaprezinc on cardiac function after myocardial infarction, and the researchers reported a beneficial effect on cardiac function measures in the treated group compared with the control group (PMID 30855449). This is a single trial in a specific clinical population, and no confirmatory trial appears in the cited set alongside it (PMID 30855449).

Study Snapshot

Adverse Events in Zinc Carnosine Trials: What Studies Report

Safety information in the cited literature comes mainly from pooled analyses and from the placebo-controlled and comparator-controlled trials described above.

• A systematic review and meta-analysis of randomized controlled trials evaluated both efficacy and safety of polaprezinc-based therapy against standard triple therapy for Helicobacter pylori eradication, and adverse events were a prespecified pooled outcome in that analysis (PMID 36235778).
• A systematic review and dose-response meta-analysis using individual patient data assessed the safety as well as the efficacy of polaprezinc in zinc deficiency, drawing on participant level records from randomized clinical trials (PMID 32316581).
• A randomized controlled study of zinc carnosine-based modified bismuth quadruple therapy recorded adverse events alongside eradication outcomes when compared with standard triple therapy (PMID 35071521).
• The randomized, double-blind, placebo-controlled, multi-center study in taste disorders provided a placebo comparison, which is the design that separates background symptom reporting from treatment-related events (PMID 19037756).

Several of these trials ran in populations with serious underlying illness, including dialysis dependence (PMID 31794152) and transplantation chemotherapy (PMID 32984946), so adverse events recorded in those settings reflect both the underlying condition and the study treatment. Zinc is also a mineral with an established upper intake range, and the dose-response analysis in zinc deficiency was structured specifically to examine how outcomes changed with the amount administered (PMID 32316581). Reported tolerability of the carnosine component is discussed separately in the PeptideU guide on carnosine side effects.

Regulatory Status in the United States

In the United States, zinc carnosine is sold as a dietary supplement. Dietary supplements are not approved by the FDA for efficacy before they reach the market; manufacturers are responsible for the safety and labelling of their products, and the agency does not evaluate supplement effectiveness claims in advance the way it does for drug applications. The clinical research cited on this page was conducted largely as investigational or clinical use within national health systems outside the United States, and none of the cited papers establishes a United States drug approval for the compound (PMID 36235778).

What the Cited Literature Does Not Settle

• Whether gastric effects reported in eradication trials come from the chelate itself or from the combination regimen it was embedded in remains open, since the comparator in those trials was a different drug regimen rather than zinc alone (PMID 35071521).
• Whether the compound outperforms simpler zinc salts was addressed only in dialysis populations, where zinc acetate hydrate served as the comparator (PMID 37840640).
• Whether carnosine-specific effects contribute beyond zinc delivery is not isolated in these trials, and the broader carnosine literature was reviewed separately in a meta-analysis of age-related disease endpoints (PMID 36722274).
• Long-term outcomes in healthy adults were not an endpoint in any of the cited randomized trials, which recruited clinical populations such as taste disorder patients (PMID 19037756).

Related Reading

• What is carnosine used for
• Carnosine side effects: what studies report
• Carnosine research overview

References

• Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial (International Journal of Nephrology, 2023)
• Comparison of zinc acetate hydrate and polaprezinc for zinc deficiency in patients on maintenance hemodialysis: A single-center, open-label, prospective randomized study (Therapeutic Apheresis and Dialysis, 2020)
• Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial (International Journal of Cancer, 2021)
• Efficacy of quadruple regimen with polaprezinc for gastric Helicobacter pylori infection eradication: protocol for a single-centre, single-blind, non-inferiority, randomised clinical trial (BMJ Open, 2020)
• The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after Helicobacter pylori Eradication: A Randomized Controlled Trial (Journal of Clinical Medicine, 2022)
• A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study (Acta Oto-Laryngologica, 2009)
• Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis (Frontiers in Bioscience, 2023)
• Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Nutrients, 2022)
• Taste disorder's management: a systematic review (Clinical Oral Investigations, 2020)
• Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data (Nutrients, 2020)
• Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study (World Journal of Clinical Cases, 2022)
• Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial (Medicine, 2019)